v3.26.1
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue [Line Items]    
Total net revenues $ 237,462 $ 197,122
Rare Disease total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 94,374 68,959
Cortrophin Gel    
Disaggregation of Revenue [Line Items]    
Total net revenues 75,119 52,850
ILUVIEN and YUTIQ    
Disaggregation of Revenue [Line Items]    
Total net revenues 19,255 16,109
Rare Disease and Brands total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 128,242 94,082
Brands    
Disaggregation of Revenue [Line Items]    
Total net revenues 12,328 25,123
Brand royalties and other revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 21,540 0
Generics and Other total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 109,220 103,040
Generic pharmaceutical products    
Disaggregation of Revenue [Line Items]    
Total net revenues 105,402 98,678
Other generic revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues $ 3,818 $ 4,362